Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995, 274: 1214-1220. 10.1001/jama.1995.03530150038031.
Loeb S, Catalona WJ: Prostate-specific antigen in clinical practice. Cancer Lett. 2007, 249: 30-39. 10.1016/j.canlet.2006.12.022.
Vickers AJ, Savage C, O’Brien MF, Lilja H: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009, 27: 398-403.
Schroder F, Kattan MW: The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008, 54: 274-290. 10.1016/j.eururo.2008.05.022.
Yoon DK, Park JY, Yoon S, Park MS, du Moon G, Lee JG, Schroder FH: Can the prostate risk calculator based on Western population be applied to Asian population?. Prostate. 2012, 72: 721-729. 10.1002/pros.21475.
Cavadas V, Osório L, Sabell F, Teves F, Branco F, Silva-Ramos M: Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol. 2010, 58: 551-558. 10.1016/j.eururo.2010.06.023.
Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW: External validation of the prostate cancer prevention trial and the European randomized study of screening for prostate cancer risk calculators in a Chinese cohort. Asian J Androl. 2012, 14: 738-744. 10.1038/aja.2012.28.
Hodge KK, McNeal JE, Stamey TA: Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol. 1989, 142: 66-70.
Terris MK, Wallen EM, Stamey TA: Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int. 1997, 59: 239-242. 10.1159/000283071.
Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997, 157: 199-202. 10.1016/S0022-5347(01)65322-9.
Chang JJ, Shinohara K, Bhargava V, Presti JC: Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol. 1998, 160: 2111-2114. 10.1016/S0022-5347(01)62254-7.
Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000, 163: 152-157. 10.1016/S0022-5347(05)67993-1.
Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F: Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007, 78: 313-317. 10.1159/000100834.
Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, Naya Y, Ichikawa T: Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology. 2006, 68: 815-819. 10.1016/j.urology.2006.05.010.
Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA: American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010, 60: 70-98. 10.3322/caac.20066.
Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schroder FH, Roobol MJ: Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the rotterdam section of the european randomized study of screening for prostate cancer. Eur Urol. 2013, [Epub ahead of print]
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009, 360: 1310-1319. 10.1056/NEJMoa0810696.
Carlson GD, Calvanese CB, Partin AW: An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology. 1998, 52: 455-461. 10.1016/S0090-4295(98)00205-2.
Eastham JA, May R, Robertson JL, Sartor O, Kattan MW: Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999, 54: 709-713. 10.1016/S0090-4295(99)00213-7.
Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW: Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology. 2001, 57: 1100-1104. 10.1016/S0090-4295(01)00980-3.
Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW: Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology. 1998, 52: 808-813. 10.1016/S0090-4295(98)00344-6.
Kim JW, Lee HY, Hong SJ, Chung BH: Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J. 2004, 45: 671-675.
Tang P, Chen H, Uhlman M, Lin YR, Deng XR, Wang B, Yang WJ, Xie KJ: A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian J Androl. 2013, 15 (1): 129-133. 10.1038/aja.2012.111.